Background: Asthma is known to display different phenotypes across the life-course, suggesting that age related changes are particularly relevant to understanding asthma pathogenesis and remission. We have previously demonstrated that a lung function phenotype associated with asthma, bronchodilator response, is reduced with age, at rate of 0.24 percent per year.
INTRODUCTION
Asthma is known to display different phenotypes across the life-course, suggesting that age related changes are particularly relevant to understanding asthma pathogenesis and remission (1) . We previously demonstrated that bronchodilator response (BDR), which is associated with asthma, is reduced with age, at rate of 0.24 percent per year (2) . The biological mediators of this age-related change are not yet understood. The metabolome may be a key source of intermediary biomarkers that contribute to clinical phenotypes in asthma, especially given that metabolites directly reflect alterations in host biochemical pathways. In fact, metabolite profiles have been associated with lung function outcomes in children with asthma (3) . In this study, our objective was to interrogate the serum metabolome to determine whether circulating metabolites mediate age-related changes in BDR in children and young adults with asthma.
METHODS
To estimate the effects of metabolite mediators, we used data from the Childhood Asthma Management Program (CAMP), a multi-center, randomized, double-masked, clinical trial designed to determine the long-term effects of treatment with budesonide, nedocromil, or a placebo for mild to moderate asthma in children (4) . A total of 1,041 children, 5-12 years of age, were enrolled in the trial between December 1993 and September 1995. Inclusion was restricted to children with a history of chronic asthma who, during a 28-day run-in period, had asthma symptoms or a low morning peak flow on 8 or more days; inclusion also required a methacholine challenge with a concentration of 12.5 mg per milliliter or less that resulted in a reduction in Metabolomic profiling was performed on serum samples in CAMP (see Supplementary Methods). Features were analyzed as measured LC-MS peak areas, and log-transformed and pareto scaled prior to analysis. After QC and data processing a total of 501 named metabolites (see Supplemental Table 1 ) were identified by matching measured mass to charge ratio and retention time with authentic reference standards.
Lung function was measured by spirometry using a Survey Tach Spirometer (Warren E. Collins; Braintree, MA) in accordance with the American Thoracic Society recommendations. Prior to assessment, the children were told to withhold short-acting bronchodilators for at least 4 h. Spirometric maneuvers were conducted with the children seated and wearing a nose clip. The measurements were calibrated for gender, age and height according to reference values. After completing baseline spirometry, the children were given 200 µg (2 puffs) of an albuterol pressurized metered-dose inhaler (pMDI) using a spacer device. Spirometry was repeated after 15 min. BDR was defined as the best forced expiratory volume in the 1st second (FEV 1 ) post-bronchodilator minus FEV 1 pre-bronchodilator, divided by FEV 1 pre-bronchodilator (expressed as a percentage).
For each individual metabolite mediator, we fit a linear regression model for bronchodilator response as the outcome and age as a predictor adjusting for the metabolite mediator and race, sex, treatment group and clinical site. We used a counterfactual framework for mediation analysis to estimate the indirect effects of age on BDR adjusting for race, sex, treatment group, and clinical site (5, 6 ). This method is implemented in the medflex package in R (7). We considered indirect effects at p < 0.05 as potential metabolite mediators of age on BDR.
RESULTS
Participant characteristics are shown in Table 1 . Participants were 64% male, and the majority were of white race/ethnicity (72% white, 12% black, 7% Hispanic, and 9% other). Participants ranged in age from 12.2 to 25.9 years. The mean BDR was 8.0% and with a standard deviation of 7.0%. The top metabolite mediators were all phosphatidylcholine plasmalogens as shown in Table 2 . Our results suggest that these metabolites may mediate the association of age with BDR (i.e., a portion of the reduction in BDR over time may be accounted for by age-related shifts in plasmalogen levels). These phosphatidylcholine plasmalogens were all highly correlated with one another (spearman r = 0.77-0.98).
We also looked at correlation patterns within our metabolite data, and determined that phosphatidyl ethanolamine (PE) metabolites and sphingomyelin (SM) metabolites are correlated with circulating PC plasmalogens. [Our main plasmalogen of interest (C36:1 PC plasmalogen), was correlated with PE Frontiers in Medicine | www.frontiersin.orgmetabolite levels (Spearman r = 0.71 for C38:2 PE, r = 0.74 for C36:2 PE plasmalogen) and with SM metabolites (Spearman r = 0.79 for C16:0 SM, r = 0.74 for C22:1 SM)]. However, these PE and SM metabolites were not mediators of the association of age with bronchodilator response (p > 0.6 for all indirect effects).
CONCLUSIONS
Plasmalogens are biologically plausible mediators of lung function responses, given their potential to alter the structural properties of lung surfactants (8) . Plasmalogen levels are reduced following exposures known to exacerbate asthma (i.e., ozone) (9) and have been associated with a range of adverse respiratory health outcomes, including bronchopulmonary dysplasia in infants (10) and COPD in adults (11) . Antioxidative effects of plasmalogens have been studied extensively both in vitro and in vivo (12), and may have relevance for bronchodilator response in asthma. Lastly, plasmalogens are biomarkers of the normal aging process (13) , which further strengthens the evidence for these metabolites as age-related mediators of physiological responses. Our study is the first to identify plasmalogens as possible mediators of age-related changes in lung function in individuals with asthma. Our findings suggest that plasmalogens may contribute to age-related asthma phenotypes, and may also serve as a potential pharmacologic target for enhancement of lung function in individuals with asthma.
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